The eosinophilia-myalgia syndrome: Status of 205 patients and results of treatment 2 years after onset

P. A. Hertzman, D. J. Clauw, L. D. Kaufman, J. Varga, R. M. Silver, H. L. Thacker, P. Mease, L. R. Espinoza, T. Pincus

Research output: Contribution to journalReview article

34 Scopus citations

Abstract

Objective: To describe the course of the eosinophilia-myalgia syndrome during a 2-year period. Design: 15 physicians completed a structured review form to describe symptoms, physical findings, laboratory data, and responses to treatments in 205 patients with the eosinophilia-myalgia syndrome at the onset of illness and after 18 to 24 months of follow-up. Setting: 15 university and private clinical practice settings. Patients: 205 patients for whom follow-up data were available and who met four criteria at diagnosis: eosinophil count of 1000 cells/mm3 or greater; presence of fasciitis, peripheral neuropathy, polyradiculopathy, interstitial pulmonary disease, pulmonary hypertension, or myocardial involvement; history of L-tryptophan consumption; and absence of other conditions that could account for these findings. Intervention: Empirical interventions by the physicians. Measurements: Symptoms, physical findings, laboratory test results, biopsy findings, radiographic reports, therapeutic interventions, and responses to these interventions. Results: After 18 to 24 months, all symptoms except cognitive changes were reported to have improved in most patients. Nearly all physical findings were also reported to have improved or resolved in most patients; only peripheral neuropathy was unchanged. No evidence of ongoing inflammatory disease was reported. Prednisone was reported to be helpful in 79% of patients who received it during the acute phase of the syndrome. No other treatment was reported to be consistently beneficial. Conclusions: 18 to 24 months after the onset of illness, most symptoms end physical findings in most patients with the eosinophilia-myalgia syndrome resolved or improved. Cognitive changes were reported to be worse in 32% of patients. Prednisone was helpful in the acute phase of illness. No treatment was clearly valuable in management of the later phase of the syndrome.

Original languageEnglish (US)
Pages (from-to)851-855
Number of pages5
JournalAnnals of internal medicine
Volume122
Issue number11
DOIs
StatePublished - Jun 1 1995

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'The eosinophilia-myalgia syndrome: Status of 205 patients and results of treatment 2 years after onset'. Together they form a unique fingerprint.

  • Cite this

    Hertzman, P. A., Clauw, D. J., Kaufman, L. D., Varga, J., Silver, R. M., Thacker, H. L., Mease, P., Espinoza, L. R., & Pincus, T. (1995). The eosinophilia-myalgia syndrome: Status of 205 patients and results of treatment 2 years after onset. Annals of internal medicine, 122(11), 851-855. https://doi.org/10.7326/0003-4819-122-11-199506010-00008